Illumina Settles BGI Patent Battles For $325M
The settlement resolves a total of eight lawsuits between the companies on genetic sequencing technology and alleged antitrust violations.
You may also be interested in...
The European Union’s antitrust commission blocked the re-acquisition of Grail by Illumina days after an FTC administrative law judge ruled in favor of the merger in the US.
The jury said the infringement, which involved patents on two-channel sequencing chemistry technology, had been “willful” and turned down Illumina’s counterclaims.
A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.